Overexpression of Transcription Termination Factor 1 is Associated with a Poor Prognosis in Patients with Colorectal Cancer

Annals of Surgical Oncology

Volumn 22, Issue , 2015, Pages 1490-1498

  Ueda, Masami ^a,b   Iguchi, Tomohiro ^a   Nambara, Sho ^a   Saito, Tomoko ^a   Komatsu, Hisateru ^a,b   Sakimura, Shotaro ^a   Hirata, Hidenari ^a   Uchi, Ryutaro ^a   Takano, Yuki ^a   Shinden, Yoshiaki ^a   Eguchi, Hidetoshi ^a   Masuda, Takaaki ^a   Sugimachi, Keishi ^a   Yamamoto, Hirofumi ^b   Doki, Yuichiro ^b   Mori, Masaki ^b   Mimori, Koshi ^a  

^a KYUSHU UNIVERSITY BEPPU HOSPITAL   (Japan)

^b OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

MYC PROTEIN; RAS PROTEIN; TRANSCRIPTION FACTOR; TRANSCRIPTION TERMINATION FACTOR 1; UNCLASSIFIED DRUG; DNA BINDING PROTEIN; MESSENGER RNA; TTF1 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; ARTICLE; CANCER PROGNOSIS; CELL MIGRATION; CELL PROLIFERATION; COLORECTAL CANCER; COLORECTAL CANCER CELL LINE; CONTROLLED STUDY; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; LIVER METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; AGED; APOPTOSIS; CANCER STAGING; CASE CONTROL STUDY; CELL MOTION; COLORECTAL TUMOR; COMPARATIVE STUDY; ENZYME IMMUNOASSAY; FOLLOW UP; GENETICS; LIVER TUMOR; METABOLISM; PATHOLOGY; PERITONEUM TUMOR; PROGNOSIS; REAL TIME POLYMERASE CHAIN REACTION; SECONDARY; SURVIVAL RATE; TUMOR CELL CULTURE; TUMOR INVASION; WESTERN BLOTTING;

AGED; APOPTOSIS; BIOMARKERS, TUMOR; BLOTTING, WESTERN; CASE-CONTROL STUDIES; CELL MOVEMENT; CELL PROLIFERATION; COLORECTAL NEOPLASMS; DNA-BINDING PROTEINS; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; LIVER NEOPLASMS; LYMPHATIC METASTASIS; MALE; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PERITONEAL NEOPLASMS; PROGNOSIS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SURVIVAL RATE; TUMOR CELLS, CULTURED;

EID: 84952872134     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-015-4652-7     Document Type: Article

References (37)

1. Washington MK. Colorectal carcinoma: selected issues in pathologic examination and staging and determination of prognostic factors. Arch Pathol Lab Med. 2008;132:1600–07.
2. O’Connell JB, Maggard MA, Ko CY. Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J Natl Cancer Inst. 2004;96:1420–25.
3. Busch H, Byvoet P, Smetana K. The nucleolus of the cancer cell: a review. Cancer Res. 1963;23:313–39.
4. Nguyen LXT, Chan SM, Ngo TD, et. al. Interaction of TIF-90 and Filamin A in the regulation of rRNA synthesis in leukemic cells. Blood. 2014;124:579–89.
5. Pahuja S, Choudhury M, Gupta U. Proliferative activity in squamous intraepithelial and invasive lesions of cervix: analysis by AgNOR staining. Indian J Pathol Microbiol. 2003;46:573–75.
6. Arora B, Jindal K, Kumar S, et al. Quantitative evaluation of AgNORs in bone tumours. Pathology. 2003;35:106–08.
7. Grandori C, Gomez-Roman N, Felton-Edkins ZA, et al. c-Myc binds to human ribosomal DNA and stimulates transcription of rRNA genes by RNA polymerase I. Nat Cell Biol. 2005;7:311–18.
8. Arabi A, Wu S, Ridderstrale K, et. al. c-Myc associates with ribosomal DNA and activates RNA polymerase I transcription. Nat Cell Biol. 2005;7:303–10.
9. Grummt I, Pikaard CS. Epigenetic silencing of RNA polymerase I transcription. Nat Rev Mol Cell Biol. 2003;4:641–49.
10. Sander EE, Mason SW, Munz C, et al. The amino-terminal domain of the transcription termination factor TTF-I causes protein oligomerization and inhibition of DNA binding. Nucleic Acids Res. 1996;24:3677–84.
11. Evers R, Smid A, Rudloff U, et al. Different domains of the murine RNA polymerase I-specific termination factor mTTF-I serve distinct functions in transcription termination. EMBO J. 1995;14:1248–56.
12. Kuhn A, Bartsch I, Grummt I. Specific interaction of the murine transcription termination factor TTF I with class-I RNA polymerases. Nature. 1990;344:559–62.
13. Langst G, Blank TA, Becker PB, et al. RNA polymerase I transcription on nucleosomal templates: the transcription termination factor TTF-I induces chromatin remodeling and relieves transcriptional repression. EMBO J. 1997;16:760–68.
14. Lessard F, Stefanovsky V, Tremblay MG, et al. The cellular abundance of the essential transcription termination factor TTF-I regulates ribosome biogenesis and is determined by MDM2 ubiquitinylation. Nucleic Acids Res. 2012;40:5357–67.
15. Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA. 2005;102:15545–50.
16. Staub E, Groene J, Heinze M, et al. An expression module of WIPF1-coexpressed genes identifies patients with favorable prognosis in three tumor types. J Mol Med (Berl). 2009;87:633–44.
17. Yokobori T, Iinuma H, Shimamura T, et al. Plastin3 is a novel marker for circulating tumor cells undergoing the epithelial-mesenchymal transition and is associated with colorectal cancer prognosis. Cancer Res. 2013;73:2059–69.
18. Mizuno H, Kitada K, Nakai K, et al. PrognoScan: a new database for meta-analysis of the prognostic value of genes. BMC Med Genomics. 2009;2:18.
19. Lai MD, Xu J. Ribosomal proteins and colorectal cancer. Curr Genomics. 2007;8:43–9.
20. Elvin P, Kerr IB, McArdle CS, et. al. Isolation and preliminary characterisation of cDNA clones representing mRNAs associated with tumour progression and metastasis in colorectal cancer. Br J Cancer. 1988;57:36–42.
21. Sharp MG, Adams SM, Elvin P, et al. A sequence previously identified as metastasis-related encodes an acidic ribosomal phosphoprotein, P2. Br J Cancer. 1990;61:83–8.
22. Chester KA, Robson L, Begent RH, et al. Identification of a human ribosomal protein mRNA with increased expression in colorectal tumours. Biochim Biophys Acta. 1989;1009:297–300.
23. Pogue-Geile K, Geiser JR, Shu M, et al. Ribosomal protein genes are overexpressed in colorectal cancer: isolation of a cDNA clone encoding the human S3 ribosomal protein. Mol Cell Biol. 1991;11:3842–49.
24. Gustafson WC, Weiss WA. Myc proteins as therapeutic targets. Oncogene. 2010;29:1249–59.
25. Vita M, Henriksson M. The Myc oncoprotein as a therapeutic target for human cancer. Semin Cancer Biol. 2006;16:318–30.
26. Jamerson MH, Johnson MD, Dickson RB. Of mice and Myc: c-Myc and mammary tumorigenesis. J Mammary Gland Biol Neoplasia. 2004;9:27–37.
27. Friedrich JK, Panov KI, Cabart P, et al. TBP-TAF complex SL1 directs RNA polymerase I pre-initiation complex formation and stabilizes upstream binding factor at the rDNA promoter. J Biol Chem. 2005;280:29551–558.
28. Poortinga G, Hannan KM, Snelling H, et al. MAD1 and c-MYC regulate UBF and rDNA transcription during granulocyte differentiation. EMBO J. 2004;23:3325–35.
29. Oskarsson T, Trumpp A. The Myc trilogy: lord of RNA polymerases. Nat Cell Biol. 2005;7:215–17.
30. Schlosser I, Holzel M, Murnseer M, et al. A role for c-Myc in the regulation of ribosomal RNA processing. Nucleic Acids Res. 2003;31:6148–56.
31. Lievre A, Bachet JB, Boige V, et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol. 2008;26:374–79.
32. Van Cutsem E, Kohne CH, Hitre E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med. 2009;360:1408–17.
33. Montagut C, Settleman J. Targeting the RAF-MEK-ERK pathway in cancer therapy. Cancer Lett. 2009;283:125–34.
34. Sears R, Nuckolls F, Haura E, et al. Multiple Ras-dependent phosphorylation pathways regulate Myc protein stability. Genes Dev. 2000;14:2501–14.
35. Pylayeva-Gupta Y, Grabocka E, Bar-Sagi D. RAS oncogenes: weaving a tumorigenic web. Nat Rev Cancer. 2011;11:761–74.
36. Yeh E, Cunningham M, Arnold H, et al. A signalling pathway controlling c-Myc degradation that impacts oncogenic transformation of human cells. Nat Cell Biol. 2004;6:308–18.
37. Amati B, Brooks MW, Levy N, et al. Oncogenic activity of the c-Myc protein requires dimerization with Max. Cell. 1993; 72:233–45.